Preclinical Studies Using the Intratumoral Aromatase Model for Postmenopausal Breast Cancer

ONCOLOGY

Volumn 12, Issue 3 SUPPL. 5, 1998, Pages 36-40

  Brodie, Angela ^a   Lu, Qing ^a   Liu, Yang ^a   Long, Brian ^a   Wang, J I Ping ^a   Yue, Wei ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000047030     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Early Breast Cancer Trials Collaborative Group: Systemic treatment of early breast cancer by hormonal cytotoxic, or immune therapy: 133 Randomized trials involving 31,000 recurrence and 24,000 deaths among 75,000 women. Lancet 339:1-15, 1995.
2. Fisher B, Costantino J, Redmond C, et at: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989.
3. Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Adjuvant Breast and Bowel Project (NSABP-14). J Natl Cancer Inst 86:527-537, 1994.
4. Jordan VC, Rowsby L, Dix CJ, et al: Dose-related effects of non-steroidal antiestrogens and estrogens on the measurement of cytoplasmic estrogen receptors in the rat and mouse uterus J Endocrinol 78:71-78, 1978.
5. Brodle A: Aromatase inhibitors in hormone-dependent cancer, in Pasqualini JR, Katzenellenbogen BS, Dekker M (eds): Molecular and Clinical Endocrinology, 1995.
6. Schwarzel WC, Kruggel W, Brodie A: Studies on the mechanism of estrogen biosynthesis: VII. The development of inhibitors of the enzyme system in human placenta. Endocrinology 92-866-880, 1973.
7. Brodie AMH, Schwarzel WC, Shaikh AA, et al: The effect of an aromatase inhibitor, 4- hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 100:1684-1695, 1977.
8. Santen RJ, Worgul TJ, Lipton A, et al: Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma: Correlation of clinical and hormonal responses. Ann Intern Med 96:94-101, 1982.
9. Biodie AMH, Njar CV: Aromatase inhibitors and breast cancer. Semin Oncol 23:10-20, 1996
10. Bhatnagar AS, Hauler A, Schieweck K, et al: Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromalase inhibitor. J Steroid Biochem Mol Biol 37:1021-1027, 1990
11. Letrozole International Trial Group (AR/ BC2). Proc Am J Clin Oncol 16.156a, 1997
12. Yue W, Zhou D, Chen S, et al: A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 54-5092-5095, 1994.
13. Lu Q, Nakmura J, Savinov A, et al: Expression of aromatase protein and messenger nbonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology 137:3061-3068, 1996.
14. Yue W, Wang J, Savinov A, et al: Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model. Cancer Res 55:3073-3077, 1995.
15. Yue W, Brodie A: MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors. J Steroid Biochem Mol Biol 44:671-673, 1993.
16. Yue W, Wang J, Hamilton CJ, et al. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res (to be published).
17. Lu Q, Yue W, Wang J, et al: The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Submitted for publication.
18. Dowsett M, Welch H, Blackman GM, et alA randomized, double blind, parallel-group trial to evaluate the effect of 'anmidex' (anastrozole) on the pharmacokinetics of tamoxifen in postmenopausal breast cancer patients (abstract) Breast Cancer Res Treat 46.30, 1997.